I agree with Drano that $IPIX’s PRs are likely b

I agree with Drano that $IPIX’s PRs are likely being positively influenced by Locust Walk. I saw a very noticeable difference in the way the 10K was written that positively and accurately communicated the value proposition of IPIX’s science. There has been what appears to be a recent sequence and rollout of PRs for both Brilacidin and Kevetrin that lay out science advancement. There are many possible reasons for $IPIX raising Authorized Shares including but not limited to a possible stock merge with another entity, a buy-in from a major pharmaceutical company as part of a strategic partnership and/or a high level BOD addition or two. The increase in AS provides flexibility in securing the most advantageous deal structure to grow the company. I believe that $IPIX retaining Locust Walk to assist in growing the company is an excellent move. I don’t understand your comment “Part of the reason to increase the authorized was for PR.” It is obvious that $IPIX did not need to increase AS for PR reasons. There are a lot of possible significant events that could be announced at any point in time which will advance the science and validate our investment in $IPIX. In the meantime many investors continue to add to their positions at what I believe is a ridiculously compressed SP.